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Abstract
Background: Breast cancer associated (BRCA) genes are critical for DNA repair. Mutations in BRCA1 and BRCA2
(BRCAm) result in loss of these repair mechanisms and potential carcinogenesis. Germline BRCAm are common in
ovarian carcinomas, particularly in platinum-sensitive disease. The increased prevalence of BRCAm in platinum-sensitive
disease is likely due to enhanced responsiveness to platinum chemotherapy from homologous recombination repair
deficiency. The purpose of this study was to explore BRCA testing, treatment patterns and survival in platinum-sensitive
recurrent (PSR) ovarian cancer.
Methods: This was an observational cohort analysis of PSR ovarian cancer treated at the Huntsman Cancer Institute
from 1995 to 2012. Germline BRCA status was ascertained through chart review and categorized as BRCAm (BRCA1/2
positive), BRCAwt (BRCA wild type or variant of uncertain significance), and untested. Treatment patterns and survival
were assessed from recurrence until death or last follow-up. The Kaplan-Meier method was used to evaluate survival
from recurrence by BRCA status. Logistic regression and COX proportional hazard model was used to estimate
predictors of BRCA testing and survival, respectively.
Results: Of the 168 PSR patients, 15 (9 %) were BRCAm, 25 (15 %) were BRCAwt, and 128 (76 %) were untested.
Median age at PSR was 56 years for BRCAm and BRCAwt (p = 0.90) and 63 years for those untested (p = 0.033 vs
BRCAm). Overall survival was similar between BRCAm and BRCAwt (median 50.4 vs 67.5 months, p = 0.86) and was
24.9 months in untested patients. Significant predictors for the likelihood of BRCA testing were age (OR = 0.93, 95 % CI
0.89, 0.97, p = 0.002), family history of breast or ovarian cancer (OR = 8.33, 95 % CI: 3.08, 22.59, p < 0.001), and cancer
diagnosis year (OR = 10.02, 95 % CI: 3.22, 31.21, p < 0.001). BRCA-tested patients had a lower risk of death versus untested
(HR 0.35, 95 % CI 0.17, 0.68, p = 0.001).
Conclusions: BRCAwt patients had similar outcomes to BRCAm patients, potentially owing to similar age at diagnosis,
representing a BRCA testing channeling bias. Younger patients, those with a family history of breast or ovarian cancer,
and those diagnosed more recently were more likely to be BRCA tested. BRCA tested patients had a lower risk of death.
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Background
It is estimated that in 2015, there will be 21,290 new
cases of ovarian cancer diagnosed in the United States
[1]. While this type of cancer is rare compared with
other types, the percentage of patients surviving 5 years
after diagnosis is only 45.6 % [1].
The current standard of care for late-stage ovarian
cancer is cytoreductive surgery followed by 6–8 cycles of
combination chemotherapy with a platinum-containing
agent such as carboplatin [2]. Patients who respond to
platinum-based therapy and experience a relapse of
ovarian cancer greater than 6 months after treatment
completion are considered to have platinum-sensitive
ovarian cancer [3]. Those who experience a relapse
during treatment or within 6 months after treatment
are considered to have platinum-resistant ovarian cancer
[4] and are unlikely to respond to additional platinum-
based treatments. However, the majority of patients at first
recurrence of ovarian cancer have platinum-sensitive
disease [3] and standard therapy in these patients consists
of retreatment with a platinum-containing regimen [2]. It
has also been found that deleterious mutations in BRCA
(breast cancer associated) genes are more prevalent in pa-
tients with platinum-sensitive ovarian cancer compared
with platinum-resistant disease [5]; this finding has impli-
cations for improving the treatment of recurrent ovarian
cancer.
BRCA1 and BRCA2 are genes that are critical for
DNA repair through homologous recombination [6].
Germline and somatic mutations in either BRCA1 or
BRCA2 result in a significant increase in genomic in-
stability and errors leading to carcinogenesis due to
homologous recombination repair deficiency [7]. Loss of
function in both genes results in cell death, whereas loss
of function in one gene allows for survival of cells with
faulty DNA repair mechanisms [8]. Therefore, patients
with germline BRCA1/2 mutations (BRCAm) have en-
hanced susceptibility to agents that target DNA, such as
platinum-containing agents, because of induction of syn-
thetic lethality [5, 9–11].
Owing to the enhanced susceptibility of platinum-
containing agents in BRCAm platinum-sensitive recur-
rent ovarian cancer and the prevalence of BRCAm in
recurrent disease, it is important to evaluate BRCA test-
ing, treatment patterns and survival in patients who may
benefit most from platinum therapy. The purpose of this
study was to assess BRCA testing patterns, treatment
patterns, and survival in patients with platinum-sensitive
recurrent ovarian cancer.
Methods
Study design and data source
This was an observational cohort study of women with
platinum-sensitive recurrent (PSR) ovarian cancer treated
at the Huntsman Cancer Institute (HCI) in Salt Lake City,
Utah. The Huntsman Cancer Institute tumor registry
(HCI-TR) was used to identify patients with site and
histology codes for epithelial ovarian cancer between
January 1, 1995 and December 31, 2012. Identified pa-
tients were linked to electronic health record data from
the University of Utah Enterprise Data Warehouse
(EDW), which provided patient demographic and clinical
information, including laboratory test results, medications,
procedures, health status and physician notes.
Study population
Included patients were 18 years and older, with a diagnosis
of epithelial ovarian cancer (ICD-10/ICD-O C56.9), fallo-
pian tube cancer (C57.0), or primary peritoneal cancer
(C48.1–48.3) in the HCI-TR, and had at least two health
care visits separated by ≥30 days with ICD-9 codes for
ovarian (183.X), fallopian tube (183.2) or primary periton-
eal cancer (158.x) at HCI. Patients who received a
platinum-based regimen (carboplatin or cisplatin) for ini-
tial systemic treatment of ovarian, fallopian tube, or pri-
mary peritoneal cancer and had a platinum-free interval
(PFI) of at least 6 months before detection of recurrence
were identified in the EDW or via chart review, classified
as PSR ovarian cancer patients and included in the final
analysis. Patients were excluded if they had a diagnosis
of in situ ovarian cancer, had no documented use of
platinum-containing agents, were platinum refractory,
had a PFI of <6 months, or had no evidence of recur-
rence. The date of the first recurrence in the EDW was
considered the index date for time to event data. The
HCI-TR provided the date, stage, pathology, histological
grade, and primary tumor site at ovarian cancer diagnosis.
Clinical characteristics such as family history of hereditary
breast or ovarian cancer and personal history of breast
cancer were assessed at recurrence using chart review in
the EDW. The University of Utah’s Institutional Review
Board and the HCI Clinical Cancer Investigations Com-
mittee approved this study.
Classification of platinum-sensitive recurrent
ovarian cancer
All patients who received platinum-based first-line treat-
ment were identified in the EDW or via chart review
and assessed for response and the PFI. PFI was defined
as the number of months from the last platinum dose to
recurrence. Those without evidence of recurrence after
first-line treatment were excluded. Patients relapsing
during first-line treatment or within 6 months of the
last platinum treatment were categorized as platinum
refractory and also excluded. Platinum sensitivity was
defined as a response to first-line platinum treatment
and a PFI of ≥6 months or physician-documented
platinum sensitivity.
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BRCA testing and status
BRCA status was ascertained through chart review. All
medical records with mention of BRCA were reviewed
by a semi-automated keyword search of the electronic
notes with a custom text search tool that searched key-
words or patterns of words using Boolean constructs.
Patients were classified as BRCAm (BRCA1/2 positive) if
a deleterious BRCA1 or BRCA2 germline mutation was
documented in the medical record. Patients were classi-
fied as BRCAwt (BRCA wild type or variant of uncertain
significance) if BRCA testing was conducted and docu-
mentation of the wild-type BRCA gene (no deleterious
mutation detected) or a variant of uncertain significance
was recorded. Lastly, patients were classified as untested
if BRCA testing was not performed or if BRCA status
was not recorded in the medical record.
Treatment patterns
Primary treatment modalities at the time of ovarian cancer
diagnosis were categorized as systemic chemotherapy, ra-
diation, or cytoreductive surgery; these treatments were
also evaluated from recurrence until death or last follow-
up. Systemic chemotherapy was further categorized as
first-line, second-line, and third-line treatment based on
the treatments received from recurrence as assessed by
chart review. Systemic treatment lines after the initial
treatment at recurrence were defined as a change in
systemic treatment (addition and/or deletion of drug)
due to disease progression, adverse events, or tolerabil-
ity. Retreatment with the same systemic treatment after
a delay in treatment as a result of an adverse event or
the inability to tolerate the regimen was not considered
a new treatment line. In patients who had a complete
response to treatment and in whom systemic treatment
was subsequently discontinued, an additional treatment
line was considered if the same or alternative systemic
treatment was restarted at subsequent disease recur-
rence/progression.
Statistical analysis
Descriptive statistical analyses, including mean and stand-
ard deviation for continuous variables and count and
percentage for categorical variables, were performed. Stu-
dent t-test and Wilcoxon rank-sum test were used for
continuous variables and Fisher’s exact test was used for
categorical variables. A significance level of 5 % was uti-
lized for this study.
Logistic regression was conducted to estimate the like-
lihood of patients receiving BRCA testing (BRCAm or
BRCAwt) versus untested patients. The covariates in the
model included age at ovarian cancer diagnosis, ethni-
city, family history of breast or ovarian cancer, personal
history of breast cancer, ovarian cancer diagnosis stage,
pathology, primary tumor site, and year of ovarian can-
cer diagnosis.
Kaplan-Meier methodology was used to evaluate sur-
vival from index date (date of PSR) until death or last
follow-up. Survival was stratified by BRCA status and
compared by log-rank test. A Cox proportional hazard
model was constructed from recurrence to death or time
of last follow-up, whichever occurred earlier, by including
patient demographics, clinical characteristics, family his-
tory or personal history of breast or ovarian cancer, year
of ovarian cancer diagnosis, and BRCA testing status
(tested vs. untested) as covariates in a single model run.
Results
Patient characteristics
There were 732 unique adult patients identified in the
HCI-TR with an ovarian cancer diagnosis between
January 1, 1995 and December 31, 2012 with at least
two visits for ovarian cancer in the EDW (Fig. 1). Of
those diagnosed with ovarian cancer, 509 patients re-
ceived a platinum agent, and of those, 168 (33 %) had
documented PSR disease (final study cohort), 94 (18 %)
had relapsed, platinum-refractory disease, and 247 (49 %)
had no evidence of disease progression.
BRCA testing and mutational status
Of the 168 PSR patients, 15 (9 %) had BRCAm, 25
(15 %) had BRCAwt, and 128 (76 %) were classified as
untested. Of the 15 BRCAm patients, 11 (73 %) had mu-
tations in BRCA1 and four had mutations in BRCA2.
BRCA testing was predominantly performed from 2006
to 2013, and only two patients received testing prior to
2006 (Fig. 2).
Demographic and clinical characteristics
Median age at recurrence was 58 years (interquartile
range [IQR]: 48–64) for BRCAm, 57 years (IQR: 50–63)
for BRCAwt and 63 years (IQR: 54–71) for untested pa-
tients, Table 1. More than 50 % of the study patients
were white (Table 1). BRCA tested patients had a higher
percentage of those with a family history of breast or
ovarian cancer compared to untested patients (65 % vs
20 %, p < 0.001). BRCA tested patients also had signifi-
cantly higher rate of a personal history of breast cancer
than untested patients (20 % vs. 5 %, p = 0.009) (Table 1),
however a statistical difference was not observed between
BRCAm and BRCAwt (33 % vs. 12 %, p = 0.13). There
were no significant differences (p < 0.05) between the
comparison groups for other clinical variables.
The median time from ovarian cancer diagnosis to
PSR disease was 20.1 months (BRCAm), 22.4 months
(BRCAwt), and 19.0 months (untested) and was not signifi-
cantly different between the comparison groups (BRCAm
vs. BRCAwt, p = 0.850) (Additional file 1: Table S1).
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Similarly, the median PFI was 12.1 months (BRCAm),
14.5 months (BRCAwt), and 13.1 months (untested) and
was not significantly different between the comparison
groups (BRCAm vs. BRCAwt, p = 0.960) (Additional file 1:
Table S1).
Treatment patterns
Systemic treatment, including chemotherapy and hormo-
nal agents, was administered in the majority of patients at
recurrence (93.3 % BRCAm, 92.0 % BRCAwt, and 78.9 %
untested, Table 2). Secondary cytoreductive surgery was
performed in 46.7 % (n = 7) of BRCAm, 52 % (n = 13) of
BRCAwt, and 40.6 % (n = 52) of untested patients. Radi-
ation therapy was used more frequently in the BRCAm
(n = 7, 46.7 %) and BRCAwt (n = 9, 36 %) patients com-
pared with untested patients (n = 25, 19.5 %). All pa-
tients in the BRCAm and BRCAwt groups received at
least one treatment (systemic, cytoreductive surgery or
radiation therapy). However, in the untested group,
2.3 % of patients (n = 3) received no treatment and
3.9 % of patients (n = 5) had unknown/missing treatments
(Table 2). The proportion of patients who received a
platinum-containing regimen any time after recurrence
was 87 % (n = 13) in the BRCAm, 76 % (n = 19) in the
BRCAwt, and 67 % (n = 118) in untested group. No statis-
tical difference in the number of treatment lines were ob-
served between BRCAm and BRCAwt groups (median 4
BRCAm vs. 3 BRCAwt, p = 0.83). The median number of
systemic treatment lines was two in the untested group
(Fig. 3).
Survival analysis
The overall survival for patients with a BRCAm was
similar to the BRCAwt group (log rank, p = 0.855), Fig. 4
Fig. 2 Number of Patients by Year of PSR Diagnosis and Year of BRCA Testing
Fig. 1 Patient Selection and BRCA Status
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Year of Ovarian Cancer Diagnosis
Median (IQR) 2007 (2004–2009) 2008 (2005–2010) 0.305 2004 (2000–2007) 0.027
Year of PSR Diagnosis
Median (IQR) 2008 (2006–2011) 2010 (2008–2012) 0.201 2006 (2003–2009) 0.043
Age at Recurrence, Years
Median age (IQR) 58 (48–64) 57 (50–63) 0.900 63 (54–71) 0.052
Mean age ± SD 56 ± 11.0 56 ± 9.7 0.903 63 ± 12.7 0.033
Age group
<60 years 8 (53.3 %) 15 (60.0 %) 0.231 50 (39.1 %) 0.039
60–74 years 5 (33.3 %) 10 (40.0 %) 55 (43.0 %)
≥75 years 2 (13.3 %) 0 23 (18.0 %)
Ethnicity
White 8 (53 %) 18 (72 %) 0.138 84 (66 %) 0.372
Hispanic 2 (13 %) 0 (0 %) 7 (5 %)
Other 0 (0 %) 2 (8 %) 6 (5 %)
Unknown 5 (33 %) 5 (20 %) 31 (24 %)
Family History of Hereditary Breast or Ovarian Cancer
No family history 0 (0 %) 14 (56 %) <0.001 103 (80 %) <0.001
Familial risk 15 (100 %) 11 (44 %) 25 (20 %)
Personal History of Breast Cancer
No history 10 (67 %) 22 (88 %) 0.126 121 (95 %) 0.003
History of breast cancer 5 (33 %) 3 (12 %) 7 (5 %)
Stage at Ovarian Cancer Diagnosis
≤2 2 (13.3 %) 5 (20 %) 0.900 21 (16.4 %) 0.917
≥3 10 (66.7 %) 15 (60 %) 87 (68.0 %)
Unknown 3 (20 %) 5 (20 %) 20 (15.6 %)
Pathology
Serous 10 (66.7 %) 18 (72 %) 0.910 77 (60.2 %) 0.759
Adenocarcinoma 1 (6.7 %) 1 (4 %) 14 (10.9 %)
Endometrioid 0 1 (4 %) 11 (8.6 %)
Other 4 (26.7 %) 5 (20 %) 26 (20.3 %)
Tumor Histologic Grade at Ovarian Cancer Diagnosis
1 and 2 2 (13.3 %) 3 (12 %) 0.847 15 (11.7 %) 0.855
3 7 (46.7 %) 8 (32 %) 68 (53.1 %)
4 2 (13.3 %) 5 (20 %) 12 (9.4 %)
Unknown 4 (26.7 %) 9 (36 %) 33 (25.8 %)
Primary Tumor Site
Ovary 12 (80 %) 20 (80 %) 0.574 113 (88.3 %) 0.363
Peritoneum 3 (20 %) 3 (12 %) 11 (8.6 %)
Fallopian tube 0 (0 %) 2 (8 %) 4 (3.1 %)
Ca-125 at Recurrence (Highest Value ±30 days), U/mL
Median Ca-125 (IQR) 195 (82–274) 49.5 (36.5–178) 0.218 90 (34–343) 0.549
Unni et al. Journal of Ovarian Research  (2016) 9:18 Page 5 of 9
and Additional file 1: Table S2. Median overall survival
from recurrence was 50.4 months in BRCAm, 67.5 months
in BRCAwt and 24.9 months in the untested group.
Predictors of BRCA testing
The significant predictors for the likelihood of BRCA
testing were age (decreased likelihood with a 1-year
increase in age, odds ratio [OR] = 0.93, 95 % CI: 0.89,
0.97, p = 0.002), family history of breast or ovarian can-
cer (increased likelihood with positive history, OR = 8.33,
95 % CI: 3.08, 22.59, p < 0.001), and year of ovarian can-
cer diagnosis (increased likelihood after 2006, OR =
10.02, 95 % CI: 3.22, 31.21, p < 0.001) (Additional file 1:
Table S3).
Table 1 Demographics and Clinical Characteristics of Study Patients (N = 168) (Continued)
ECOG score
Median ECOG (IQR) 1 (0–1) 0 (0–1) 0.457 1 (0–1) 0.634
ECOG group
≤2 6 (40 %) 14 (56 %) 0.514 34 (26.6 %) 0.490
≥3 0 0 2 (1.6 %)
Unknown 9 (60 %) 11 (44 %) 92 (71.9 %)
Initial Treatment at Ovarian Cancer Diagnosis
Chemotherapy 7 (46.7 %) 12 (48 %) 0.547 50 (39.1 %) 0.504
Neoadjuvant chemotherapy 4 (26.7 %) 3 (12 %) 11 (8.6 %)
Radiation therapy 0 0 2 (1.6 %)
Primary debulking or cytoreductive surgery 9 (60 %) 23 (92 %) 110 (86 %)
Missing 0 0 1 (0.8 %)
Duration of Follow-up, Days
Median (IQR) 1064 (656–2231) 981.5 (434–1546) 0.419 490 (219–1015) 0.005
*BRCAm vs. BRCAwt Fisher’s exact test for categorical variables, Wilcoxon rank-sum or t-test for continuous variables; **BRCAm vs. Untested Fisher’s exact test for
categorical variables, Wilcoxon rank-sum or t-test for continuous variables
Table 2 Systemic Treatment, Surgery, Radiation and Utilization Post-Recurrence
Treatment Type BRCAm BRCAwt Untested
n = 15 % or
Range
p-Value n = 25 % or
Range




Systemic treatment received, n 14 93.3 % ref 23 92.0 % 0.876 101 78.9 % 0.138
Missing/unknown, n 1 6.7 % - 1 4.0 % - 16 12.5 % -
Median number of treatment lines (IQR) 4 (2–4) 0–6 ref 3 (1–5) 0–11 0.832 2 (1–3) 0–6 0.001
Platinum-containing regimen
post-recurrence, n
13 86.7 % ref 19 76.0 % 0.404 86 67.2 % 0.098
Cytoreductive Surgery
Secondary cytoreductive surgery, n 7 46.7 % ref 13 52.0 % 0.744 52 40.6 % 0.655
Missing/unknown, n 0 0.0 % - 0 0.0 % - 5 3.9 % -














Radiation therapy, n 7 46.7 % ref 9 36.0 % 0.506 25 19.5 % 0.027
Missing/unknown, n 0 0.0 % - 0 0.0 % - 5 3.9 % -
















(Surgery, Radiation, Systemic), n
0 0.0 % - 0 0.0 % - 3 2.3 % -
Total Unknown/Missing
(Surgery, Radiation, Systemic), n
0 0.0 % - 0 0.0 % - 5 3.9 % -
*BRCAm vs. BRCAwt;**BRCAm vs. Untested
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Predictors of survival from platinum-sensitive recurrence
Patients who received a BRCA test had a lower risk of
death than untested patients (hazard ratio [HR] = 0.35,
95 % CI 0.17, 0.68, p = 0.001). Also, the risk of death in-
creased by 2 % for each increasing year of age (HR =
1.020, 95 % CI 1.001, 1.040, p = 0.039) (Additional file 1:
Table S4).
Discussion
This study provides a unique perspective into BRCA
testing, clinical characteristics, treatment patterns, and
survival outcomes in unselected, consecutive patients
with PSR ovarian cancer. These data suggest that tested
patients are younger at diagnosis, receive more treat-
ment lines and have improved survival compared with
untested patients.
This study demonstrates that in an academic oncology
center with extensive genetic services support, approxi-
mately 24 % (n = 40) of patients with PSR ovarian cancer
(n = 168) were tested for BRCAm. Of those who were
tested, 37.5 % (n = 15) tested positive for a deleterious
mutation in BRCA1 or BRCA2, indicating a high pre-
test probability for BRCAm, since it is thought that only
12–15 % of invasive ovarian cancers are associated with
BRCAm [12, 13]. The high probability for BRCAm was
also supported by other factors such as family history of
breast or ovarian cancer, which was observed in all
BRCAm patients and is known to be positively associ-
ated with BRCA testing.
BRCA1/2 testing was made commercially available in
1996 by Myriad Laboratories, Inc. Utilization of BRCA
testing increased during the study period, with more pa-
tients with PSR ovarian cancer being BRCA tested after
2006, which is substantiated by outside reports of in-
creased utilization of BRCA testing [14]. Also, it was in
2006 that HCI instituted a Hereditary Risk Evaluation
Program, which may have contributed to increased
BRCA testing in subsequent years and may account for
the variation in the number of tested patients before and
after 2006.
These data affirm that patients with a family history of
hereditary breast or ovarian cancer are more likely to
have been BRCA tested, with all BRCAm patients having
a history compared with 44 % of BRCAwt and 20 % of
untested patients. Additionally, BRCAm patients (33 %,
n = 5) were more likely to have a personal history of
breast cancer, either prior to ovarian cancer diagnosis or
concurrently, compared to untested (5 %, n = 7) and
BRCAwt patients (20 %, n = 3).
BRCA-tested patients were also significantly younger
than untested patients. The median age for BRCAm pa-
tients was similar to those in other reports [15]. The
similar age of BRCAm and BRCAwt patients potentially
represents a channeling bias as patients diagnosed at a
younger age are more likely have a BRCAm and clinicians
would be more likely to offer genetic testing to younger
patients based on guideline recommendations [2].
Overall, younger age at diagnosis of ovarian cancer,
family history of hereditary breast or ovarian cancer, and
personal history of breast cancer were all significant pre-
dictors of BRCA testing in this population and suggests
that testing was motivated by genetic risk assessment.
Additionally, based on other population-based studies
indicating a BRCAm rate of 12–15 % [12, 13] in invasive
ovarian cancer, our cohort would be expected to contain
20–25 BRCAm carriers. Therefore, over the study period,
genetic risk assessment and BRCA testing potentially dis-
covered 60–75 % of the expected BRCAm carriers. How-
ever, the expected BRCAm rate may be higher in patients
with PSR ovarian cancer. Universal BRCA testing is now
recommended for all patients with high-grade serous
ovarian cancer and would have likely identified additional
BRCA carriers [2].
Our study identified 11 BRCA1 and 4 BRCA2 muta-
tion carriers thus a BRCA1-to-BRCA2 ratio of ~3:1.
There are geographic and ethnic differences in BRCA1
and BRCA2 mutations [16]. Common founder BRCA1/2
Fig. 3 Systemic Treatment Lines Received for Platinum-Sensitive
Recurrence Date
Fig. 4 Kaplan-Meier Survival Estimates from Platinum-Sensitive
Recurrence Date
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mutations with a significant role in the population occur
in Ashkenazi Jews, as well as in Iceland, Russia, Germany,
Hungary, Norway, Finland, Sweden, Denmark, France, the
Netherlands, and the UK [16]. Overall, 8–40 % of all
BRCA1 mutations have been identified in families from
the UK, USA, France, Germany, Italy, and the Netherlands
[16]. In 13 studies containing at least 60 families in which
one or more cases of ovarian cancer were ascertained, the
frequency of BRCA1 ranged from 24.2 to 76.2 % and the
frequency of BRCA2 ranged from 1.0 to 16.7 % [16]. The
overall ratio of BRCA1 to BRCA2 mutations ranged from
2:1 to 62:1 [16]. These 13 studies mostly took place in
European countries (aside from Australia and the USA).
Thus, the BRCA1: BRCA2 ratio of 3:1 in our study is con-
sistent given that the majority of Utah inhabitants are of
Northern European descent.
Improved ovarian cancer survival outcomes in BRCAm
carriers have been reported [15, 17]. The largest and
most recent meta-analysis demonstrated that BRCA1
and BRCA2 mutations have positive prognostic effects
on ovarian cancer overall and progression-free survival
[18]. The results of this meta-analysis revealed that
BRCA1 mutation carriers were associated with better
overall survival than non-carriers, with a pooled HR of
0.76 (95 % CI: 0.70, 0.83) [18]. However, BRCA2 muta-
tion carriers were associated with even better survival
outcomes compared with non-carriers, with a pooled
HR of 0.58 (95 % CI: 0.50, 0.66) [18]. Platinum-free sur-
vival was also improved in BRCA1 mutation carriers
(HR = 0.65; 95 % CI: 0.52, 0.81) and BRCA2 mutation
carriers (HR = 0.61; 95 % CI: 0.47, 0.80) [18]. Though
we did not evaluate survival in BRCA1 and BRCA2 pa-
tients because of sample size limitations, median sur-
vival from recurrence was not significantly different
between BRCAm and BRCAwt patients in our study,
whereas it was lower in untested patients.
These data indicated that tested patients had better
OS than untested patients. However, this result should
be interpreted with caution as the tested patients tended
to be younger and their diagnoses were more recent and
thus changes in treatment practice may be contributing.
Furthermore, these data support the necessity for testing
patients to ensure early diagnosis and optimization of
the treatment options.
Potentially contributing to the improved survival, tested
patients also received more systemic treatment lines after
diagnosis of PSR ovarian cancer than untested patients.
However there were no significant differences between
BRCAm and BRCAwt patients, potentially reflecting the
lack of available targeted therapies. The proportion of pa-
tients who received a platinum-containing regimen at any
time after PSR diagnosis was 87 % (n = 13) in BRCAm,
76 % (n = 19) BRCAwt, and 67 % (n = 118) in untested pa-
tients. Utilization of secondary cytoreductive surgery and
palliative radiation therapy was similar between BRCAm
(46.7 %) and BRCAwt (36 %) patients; however, fewer
untested patients received palliative radiation therapy
(19.5 %). The increased use of palliative radiation therapy
in BRCA tested patients may be partially explained by
their increased duration of survival and therefore in-
creased opportunity to receive radiation therapy.
There are several limitations of this research that
should be considered when interpreting the results of
this study. These results were from a single institution
and may not be generalizable to a larger population or
geographic area where clinical practices differ. Further-
more, the demographic composition of the study resulted
in under-representation of some demographic categories
and small sample sizes for some groups, such as races
other than Caucasian/white, precluding meaningful com-
parisons across some categories of interest. The practice
patterns observed at the HCI, a National Cancer Institute
Designated Center and member of the National Compre-
hensive Cancer Network, may not be typical of those in
other types of treatment facilities and institutions.
Data from medical charts and tumor registries can be
subject to missing data and coding errors. Although
most of the demographic and clinical characteristics and
treatment patterns of interest for this study were reported
as known, there were several variables in the overall
population with non-negligible missing or unknown
values such as race/ethnicity, stage at ovarian cancer
diagnosis, and ECOG performance status, which may
have an impact on survival.
Lastly, this study was limited by the small number of
BRCA tested patients (n = 40) versus the larger cohort of
untested patients (n = 128) and in particular, the resulting
small sample size of BRCAm carriers (n = 15) which did
not allow for meaningful characterization of survival and
treatment patterns between BRCA1 and BRCA2 mutation
carriers. An inherent problem of observational studies is
the possibility of selection bias; as this was an observa-
tional study of real-world BRCA testing practices, the
BRCA test selection bias (younger age and more recent
year of diagnosis) made it difficult to compare differences
between BRCAm and BRCAwt patients. Also, owing to
the limitations of available observational data, the untested
group was used as a comparison group; this group was as-
sumed to contain predominantly non-BRCAm carriers.
Conclusion
This study demonstrates in an academic oncology center
with extensive genetic services support that BRCA testing
rates increased during the study period and that the likeli-
hood of BRCA testing increased with lower age, positive
family history, and presenting time. However, wider BRCA
testing may have identified additional BRCA carriers.
Patients tested for BRCAm had greater median overall
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survival rates versus untested patients and a corre-
sponding greater number of systemic treatment lines.
BRCAwt patients had similar outcomes to BRCAm pa-
tients. Overall, this study continues to demonstrate the
distinct clinical behavior of BRCA-mutated ovarian
cancer and underscores the importance of appropriate
genetic risk assessment and BRCA testing.
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